HNE samples were procured from subjects recruited through the Cincinnati Children's Hospital Medical Center CF Research Center. All methods described here have been approved by the Institutional Review Board (IRB) of Cincinnati Children's Hospital Medical Center. Written consent was obtained from all subjects prior to testing.
1. Prepare Expansion Media and Antibiotic Media
2. Prepare Differentiation Media
3. Coat Culture Dishes and Plate Feeder Fibroblasts
NOTE: Perform all steps under clean conditions in the biosafety cabinet.
4. Obtain and Process HNE Sample
5. Process and Expand HNE Cells in Dishes
NOTE: Perform all steps under clean conditions in the biosafety cabinet.
6. Passage HNE Cells
7. Seeding Cells for HNE Spheroid Cultures
NOTE: Carry out all procedures in this step, other than centrifugation, in a clean biosafety cabinet.
8. Differentiate and Mature HNE Spheroids
9. Pretreat, Stimulate, and Image HNE Spheroids for Analysis
10. Analyze HNE Spheroid Images
HNEs should attach to the culture dish and form small islands of cells within 72 h of seeding; examples of good and poor island formation at one week are shown in Figure 1A and 1B, respectively. These islands should expand to cover the dish over the course of 15-30 days. Small or suboptimal samples may take longer, and often will not yield useful spheroids. Contamination with infectious agents is evidenced by deep yellow/cloudy media, failure of the cells to attach to the culture dish, and/or direct visualization of fungi/bacteria. Any contaminated cultures should be immediately discarded to avoid cross-contamination.
Within the first 3-4 days of culture in the basement membrane matrix, small cystic structures should begin to form in the matrix. These will mature over approximately 10 days into intact spheroids demonstrating a thin wall and a luminal surface. If plated at the described density, successful cultures will contain 50-100 spheroids per matrix drop. The lumens may be relatively clear (Figure 1C) or filled with cellular debris and mucus (Figure 1D); the former is more common in spheroids with wild-type CFTR (wtCFTR), and the latter in CF spheroids. Masking to delineate the luminal area of the spheroids in Figure 1C and 1D is demonstrated in Figure 1E and 1F, respectively. Examples of poorly formed/unsuccessful spheroid cultures are provided in Figure 1G and 1H.
Representative functional data for wild type and F508del CFTR homozygous HNE spheroids is shown in Figure 2A and 2B, respectively; this data is representative of >10 unique HNE samples in wild type and F508del CFTR homozygous subjects30. In short, spheroids with functional CFTR swell, while those with dysfunctional CFTR swell significantly less, or may shrink. Specifically, spheroids from subjects with wtCFTR should swell over an hour when stimulated, and should swell less or shrink if stimulated in the presence of the CFTR inhibitor Inh172. Conversely, spheroids from a subject homozygous for F508del CFTR should either shrink or swell very slightly, with increased swelling (or less shrinking) when pharmacologically corrected with the CFTR modulators VX809 and VX770. Previous analyses of spheroid reliability both within and between subjects of the same genotype demonstrate functional segregation of CFTR genotypes and modest variability in repeated measures30.
Media Component | Stock Solution | Amount | Storage |
Expansion Media | |||
DMEM / F-12 Nutrient Mixture "Base Media" | Use as is | 2x 500 mL containers | Store at 4 ºC up to manufacturer expiration date |
Fetal Bovine Serum | Use as is | 50 mL | Store at -20 ºC up to manufacturer expiration date |
Cholera Toxin | 10 mg in 1 mL of sterile water | 1 µL | Store stock at -20 ºC up to six months |
Epidermal Growth Factor | 500 µg in 1 mL of sterile water | 20 µL | Store stock at -20 ºC up to six months |
Hydrocortisone | 0.4 mg in 400 µL of sterile water | Entire 400 µL aliquot | Make fresh with each batch. Store powder at room temperature up to manufacturer expiration date |
Adenine | 24 mg in 1 mL of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at room temperature up to manufacturer expiration date |
Y-27632 | 3.2 mg in 1 mL of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date |
Antibiotic Media | |||
Amphotericin B | Use as is | 1.2 mL | Store at 4 ºC up to manufacturer expiration date |
Ceftazidime | 15 mg in 1 mL of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date |
Tobramycin | 15 mg in 1 mL of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date |
Vancomycin | 15 mg in 1 mL of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date |
Table 1: Components of Expansion and Antibiotic Media.
Media Component | Stock Solution | Amount | Storage |
DMEM / F-12 Nutrient Mixture "Base Media" | Use as is | 2x 500 mL containers | Store at 4 ºC up to manufacturer expiration date |
Ultroser-G | 20 mL of sterile water in a single, 20 mL bottle of lyophilized Ultroser-G | Entire 20 mL aliquot | Make fresh with each batch. Store powder at 4 ºC up to manufacturer expiration date |
Fetal Clone II | Use as is | 20 mL | Store at -20 ºC up to manufacturer expiration date |
Pen Strep | Use as is | 10 mL | Store at -20 ºC up to manufacturer expiration date |
Bovine Brain Extract | Use as is | 2.48 mL | Store at -20 ºC up to manufacturer expiration date |
Transferrin | Use as is | 250 µL | Store at -20 ºC up to manufacturer expiration date |
Insulin | Use as is | 250 µL | Store at -20 ºC up to manufacturer expiration date |
Ethanolamine | Use as is | 15 µL | Store at room temperature up to manufacturer expiration date |
Epinephrine | 2.75 mg in 1 ml of sterile water | Entire 1 mL aliquot | Make fresh with each batch. Store powder at 4 ºC up to manufacturer expiration date |
Triiodothyronine | 8.4 mg in 50 µL of DMSO | Entire 50 µL aliquot | Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date |
Hydrocortisone | 7.24 mg in 1 mL of ethanol | 1 µL | Store stock at -20 ºC up to six months |
Phsophoryletheanolamine | 35.25 mg in 1 mL of sterile water | 1 µL | Store stock at -20 ºC up to six months |
Retinoic Acid | 3 mg in 1 mL of DMSO | 1 µL | Store stock at -20 ºC up to six months |
Table 2: Components of Differentiation Medium.
Figure 1: HNE Expansion and Structural Characteristics of HNE Spheroids. Brightfield images of HNE expansion cultures taken seven days after plating demonstrate successful (white arrow, panel A) and unsuccessful (panel B) HNE colony formation on a feeder fibroblast background. Successful wtCFTR and F508del homozygous spheroids are shown in panels C and D, respectively. Masking to delineate the luminal area of spheroids from C/D is provided in panels E and F, respectively. Unsuccessful spheroid cultures are characterized by small, disorganized cellular debris (panel G) and/or disorganized clumps of cells (panel H). Scale bar = 100 µm. Please click here to view a larger version of this figure.
Figure 2: Functional Characteristics of HNE Spheroids. Representative functional responses of wtCFTR spheroids from a single donor, when stimulated with forskolin/IBMX with/without the presence of the CFTR inhibitor Inh172 are shown in panel (A) Each point represents the response in a single spheroid. Representative functional responses of F508del homozygous spheroids from a single donor, when stimulated with forskolin/IBMX with/without the presence of VX809 and VX770 are shown in panel (B). Error bars = SEM. **p <0.01; ***p <0.001. Please click here to view a larger version of this figure.
1.5 mL Eppendorf Tube | USA Scientific | 4036-3204 | |
150 mL Filter Flask | Midsci | TP99150 | To filter Media |
15 mL Conical Tube | Midsci | TP91015 | |
1 L Filter Flask | Midsci | TP99950 | To filter Media |
35 mm Glass-Bottom Dish | MatTek Corporation | P35G-0-20-C | Optional |
3-Isobutyl-1-Methylxanthine (IBMX) | Fisher Scientific | AC228420010 | Prepare a 100 mM stock solution of 22.0 mg in 1 mL of DMSO |
50 mL Conical Tube | Midsci | TP91050 | |
Accutase | Innovative Cell Technologies, Inc. | AT-104 | Cell detachment solution |
Adenine | Sigma-Aldrich | A2786-25G | See Table 1 |
Amphotericin B | Sigma-Aldrich | A9528-100MG | See Table 1 |
Bovine Brain Extract (9mg/mL) | Lonza | CC-4098 | See Table 2 |
Ceftazidime hydrate | Sigma-Aldrich | C3809-1G | See Table 1 |
Cell Scrapers 20 cm | Midsci | TP99010 | |
CFTR Inh172 | Tocris Bioscience | 3430 | Prepare a 10 mM stock solution of 4.0 mg in 1 mL of DMSO |
Cholera Toxin B (From Vibrio cholerae) | Sigma-Aldrich | C8052-.5MG | See Table 1 |
CYB-1 | Medical Packaging Corporation | CYB-1 | Cytology brush |
Dimethyl sulfoxide (DMSO) | Sigma-Aldrich | D5879-500ML | |
Dulbecco's Modified Eagle Media (DMEM)/F12 Hepes | Life Technologies | 11330-057 | Base Medium; See Tables 1 and 2 |
Epidermal Growth Factor (Recombinant Human Protein, Animal-Origin Free) | Thermo Fisher Scientific | PHG6045 | See Table 1 |
Epinephrine | Sigma-Aldrich | E4250-1G | See Table 2 |
Ethanol | Fisher Scientific | 2701 | |
Ethanolamine | Sigma-Aldrich | E0135-500ML | 16.6 mM solution; See Table 2 |
Ethylenediaminetetraacetic Acid (EDTA) | TCI America | E0084 | |
Fetal Bovine Serum (high performance FBS) | Invitrogen | 10082147 | See Table 1 |
Forskolin | Sigma-Aldrich | F6886-50 | Prepare a 10 mM stock solution of 4.1 mg in 1 mL of DMSO |
Growth Factor-Reduced Matrigel | Corning, Inc. | 356231 | Corning Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix, Phenol Red-Free, LDEV-Free, 10 mL. |
Hemacytometer | Hausser Scientific | 1483 | |
Human Collagen Solution, Type I (VitroCol; 3 mg/mL) | Advanced BioMatrix | 5007-A | Collagen solution |
HyClone (aka FetalClone II) | GE Healthcare | SH30066.03HI | See Table 2 |
Hydrocortisone | StemCell Technologies | 07904 | See Tables 1 and 2 |
Insulin, human recombinant, zinc solution | Life Technologies | 12585014 | 4 mg/mL solution; see Table 2 |
IVF 4-Well Dish, Non-treated | NUNC (via Fisher Scientific) | 12566350 | 4-well plate for spheroids; similar well size to a 24-well plate |
MEF-CF1-IRR | Globalstem | GSC-6001G | Irradiated murine embryonic fibroblasts |
Metamorph 7.7 | Molecular Devices | Analysis Software; https://www.moleculardevices.com/systems/metamorph-research-imaging/metamorph-microscopy-automation-and-image-analysis-software for a quote | |
Olympus IX51 Inverted Microscope | Olympus Corporation | Discontinued | Imaging Microscope. Replacment: Olympus IX53, https://www.olympus-lifescience.com/pt/microscopes/inverted/ix53/ for a quote |
Pen Strep | Life Technologies | 15140122 | See Table 2 |
Phsophoryletheanolamine | Sigma-Aldrich | P0503-5G | See Table 2 |
Retinoic Acid | Sigma-Aldrich | R2625-50MG | See Table 2 |
Rhinoprobe | Arlington Scientific, Inc. | 96-0905 | Nasal curette |
Slidebook 5.5 | 3i, Intelligent Imaging Innovations | Discontinued | Imaging Software. Replacement: Slidebook 6, https://www.intelligent-imaging.com/slidebook for a quote |
Sterile Phosphate Buffered Saline (PBS) | Thermo Fisher Scientific | 20012050 | |
Sterile Water | Sigma-Aldrich | W3500-6X500ML | |
Tissue Culture Dish 100 | Techno Plastic Products | 93100 | Tissue culture dish for expansion |
Tobramycin | Sigma-Aldrich | T4014-100MG | See Table 1 |
Transferrin (Human Transferrin 0.5 mL) | Lonza | CC-4205 | See Table 2 |
Triiodothryonine | Sigma-Aldrich | T6397-1G | 3,3′,5-Triiodo-L-thyronine sodium salt [T3]; See Table 2 |
Trypsin from Porcine Pancreas | Sigma-Aldrich | T4799-10G | |
Ultroser-G | Crescent Chemical (via Fisher Scientific) | NC0393024 | 20 mL lypophilized powder; See Table 2 |
Vancomycin hydrochloride from Streptomyces orientalis | Sigma-Aldrich | V2002-5G | See Table 1 |
VX770 | Selleck Chemicals | S1144 | Prepare a 1 mM stock solution of 0.4 mg in 1 mL of DMSO |
VX809 | Selleck Chemicals | S1565 | Purchase or prepare a 10 mM stock solution of 4.5 mg in 1 mL of DMSO |
Y-27632 Dihydrochloride ROCK inhibitor | Enzo LifeSciences | ALX-270-333-M025 | See Table 1 |
While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.
While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.
While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.